share_log
Reuters ·  Apr 30 08:30
NRX Pharmaceuticals (Nasdaq:Nrxp) Announces Promising Findings in Phase 2B/3 Clinical Trial of NRX-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment